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I nsulin resistance is a major public health concern because it can lead to type 2 diabetes, dyslipidemias, and arteriosclerotic heart disease. The liver plays a central role in obesity-related insulin resistance, 1 reflected in impaired insulin suppression of hepatic glucose production by down-regulating gluconeogenesis 2 and inhibiting glycogenolysis. 3, 4 Insulin also promotes de novo hepatic lipogenesis through activation of the transcription factor SREBP1c, 5 which is not reduced in insulin-resistant states, but rather increased due to compensatory hyperinsulinemia. 6 Endocannabinoids and cannabinoid receptor-1 (CB 1 ) contribute to obesity and its metabolic consequences, as indicated by the effectiveness of CB 1 antagonists in reducing body weight and improving insulin resistance and dyslipidemia in subjects with the metabolic syndrome. [7] [8] [9] [10] Furthermore, CB 1 -deficient (CB 1 Ϫ/Ϫ ) mice are resistant to high-fat diet (HFD)-induced obesity, fatty liver, insulin resistance, and dyslipidemia despite a caloric intake similar to that in controls. 11, 12 Whereas hepatocyte-specific CB 1 knockout (hCB 1 Ϫ/Ϫ ) mice do become obese on HFD, they remain insulin sensitive, suggesting the involvement of hepatic CB 1 in whole body insulin resistance. 13 Here we explored the involvement of hepatic CB 1 in HFD-induced hepatic insulin resistance using a euglycemic hyperinsulinemic clamp. Parallel experiments in hCB 1 Ϫ/Ϫ mice and mice with hepatocyte-specific transgenic overexpression of CB 1 on a global CB 1 knockout background (htgCB 1 Ϫ/Ϫ mice) indicated that hepatic CB 1 activation is both necessary and sufficient to account for diet-induced hepatic insulin resistance, independent of body weight. The results further indicate that CB 1 -induced insulin resistance is secondary to endoplasmic reticulum (ER) stress, triggered by activation of the Bip/PERK/eIF2␣ protein translation pathway, with CB 1 inducing serine-307 phosphorylation of IRS1 and activation of the serine/threonine phosphatase Phlpp1, which reverses insulin-induced akt-2 phosphorylation. Finally, we show that the hyperinsulinemia that accompanies CB 1 -induced insulin resistance is due to decreased insulin clearance, secondary to down-regulation of the insulin-degrading enzyme (IDE) in the liver.
Materials and Methods Mice
Male C57Bl/6J mice and genetically modified strains backcrossed 10 times to a C57BL/6J background were bred from heterozygote pairs to allow for littermate controls. All experiments were approved by the institutional animal care and use committee. CB 1 Ϫ/Ϫ and hCB 1 Ϫ/Ϫ mice were generated as described. 13 
Intraperitoneal Glucose Tolerance and Insulin Sensitivity Tests
Mice fasted overnight were injected intraperitoneally with 2 g/kg glucose. Tail blood was collected at indicated time points and glucose levels were determined using a glucometer (Elite; Bayer, Pittsburgh, PA). One week later, mice fasted for 6 hours before the test received an intraperitoneal injection of insulin (0.75 U/kg; Eli Lilly, Indianapolis, IN) and blood glucose levels were determined.
Hyperinsulinemic Euglycemic Clamp
Clamps and glucose tracer analyses in conscious, cannulated mice were performed as described. 15 
Plasma Hormone Levels
Total plasma insulin was analyzed by the Milliplex Map Mouse Endocrine Panel, human insulin levels were assessed via the Ultrasensitive Human Insulin Assay, and C-peptide in plasma was measured with the Mouse C-Peptide Multiplex Assay (Millipore, Billerica, MA).
Culture of Primary Hepatocytes and Gene Knockdown
Primary mouse hepatocytes were prepared by collagenase perfusion as described. 16 After overnight attachment, cells were transfected with Phlpp1 small interfering RNA (siRNA; Qiagen, Valencia, CA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or infected with GFP-eIF2␣-short hairpin RNA (shRNA) lentivirus at a multiplicity of infection of 50 for 48 hours. Cells were serum starved for 4 hours and subjected to various treatments. The degree of knockdown relative to mocktransfected cells (60%-70%) was verified by real-time polymerase chain reaction (PCR) of target messenger RNA (mRNA). Primary human hepatocytes were isolated by collagenase digestion of human donor livers not used for transplant. 17 Reverse-Transcription PCR CB 1 R mRNA expression was assessed by reverse-transcription PCR and normalized with ␤-actin as described previously. 18 Primer sequences are provided in Supplementary  Table 1 .
Quantitative Real-Time PCR
We used a model PTC-200 Peltier Thermal Cycler (MJ Research, Waltham, MA) and iTaq SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA). Predesigned mouse GAPDH, phosphoenolpyruvate carboxykinase (PEPCK), G6pc, and Glut4 primers were purchased from Qiagen (Valencia, CA). Gene expression values were calculated based on the ⌬⌬Ct method.
Western Blotting and Immunoprecipitation
Protein was extracted from frozen brain or liver samples or from cultured hepatocytes. Western blotting was performed as described, 18 and immunoprecipitation was performed using the Pierce (Rockford, IL) Seize Classic (G) Immunoprecipitation Kit. 
Results

Anandamide Causes CB 1 -Mediated Glucose Intolerance and Whole Body Insulin Resistance
To explore the role of endocannabinoids in glucose homeostasis, we examined the effect of acute in vivo treatment with anandamide on whole body glucose tolerance and insulin sensitivity in mice kept on STD. In wild-type mice, anandamide (10 mg/kg intraperitoneally) caused acute glucose intolerance and insulin resistance, with no such effects observed in CB 1 Ϫ/Ϫ mice ( Figure 1A ). However, the previously described effects of anandamide reappeared in htgCB 1 Ϫ/Ϫ mice, in which the overexpression of hepatic CB 1 matched the HFD-induced increase in hepatic CB 1 in wild-type mice, 13 and resulted in increased CB 1 agonist efficacy quantified by GTP␥S binding ( Figure 1C ). HtgCB 1 Ϫ/Ϫ mice had elevated fasting blood glucose and insulin levels relative to CB 1 Ϫ/Ϫ littermates, while the rest of their hormonal/metabolic profile and body composition were similar (Supplementary Figure 1) . We next tested the effect of HFD on glucose tolerance and insulin resistance. HtgCB 1 Ϫ/Ϫ mice on HFD remained lean and had a moderate increase in liver triglyceride levels (Supplementary Figure 1) . Again, wild-type and htgCB 1 Ϫ/Ϫ mice, but not CB 1 Ϫ/Ϫ mice, developed marked HFD-induced glucose intolerance/insulin resistance ( Figure 1B ), indicating that activation of hepatic CB 1 induces glucose intolerance and insulin resistance and mediates the similar effects of HFD.
Hepatic CB 1 Are Necessary for Diet-Induced Hepatic Insulin Resistance
To assess the contribution of the liver to CB 1 -mediated changes in glucose homeostasis, we conducted euglycemic hyperinsulinemic clamps in wild-type, CB 1 Ϫ/Ϫ , hCB 1 Ϫ/Ϫ , and htgCB 1 Ϫ/Ϫ mice on STD or HFD. Wild-type mice became obese on HFD and displayed hepatic insulin resistance, as indicated by the marked reduction in glucose infusion rates, resulting from the reduced ability of insulin to suppress hepatic glucose production. Whole body glucose uptake tended to decrease in mice receiving HFD, but this did not reach statistical significance ( Figure  2 ). CB 1 Ϫ/Ϫ mice receiving HFD remained lean and insulin sensitive, with hepatic glucose production, glucose infusion rate, and whole body glucose uptake that were similar to their controls receiving STD. Interestingly, hCB 1 Ϫ/Ϫ mice receiving HFD also remained insulin sensitive despite becoming as obese as wild-type mice, 13 whereas htgCB 1 Ϫ/Ϫ mice receiving HFD were as insulin resistant as wild-type mice receiving HFD despite remaining lean, with marked reduction of glucose infusion rate and a modest decrease in whole body glucose uptake ( Figure 2 and Supplementary Figure 1 ). This indicates that hepatic insulin resistance depends on CB 1 activity and is independent of adiposity.
Hepatic CB 1 Are Sufficient to Induce Hepatic Insulin Resistance Associated With Reduced Insulin Clearance
HtgCB 1
Ϫ/Ϫ mice on STD had elevated fasting blood glucose relative to their CB 1 Ϫ/Ϫ littermates ( Figure  3A ). When subjected to hyperinsulinemic clamp, basal hepatic glucose production and plasma insulin levels were significantly higher than in CB 1 Ϫ/Ϫ littermates ( Figure 3A Ϫ/Ϫ , and htgCB 1 Ϫ/Ϫ mice were subjected to an intraperitoneal glucose tolerance test (GTT) and a week later an insulin sensitivity test (IST). Overnight fasted mice received an intraperitoneal injection of vehicle (open symbols) or 10 mg/kg anandamide (filled symbols). Ten minutes later, the animals received 2 g/kg glucose intraperitoneally, followed by blood glucose measurements at the indicated time points. One week later, each mouse received an intraperitoneal injection of vehicle or 10 mg/kg anandamide. Ten minutes later, 0.75 U/kg insulin was injected and blood glucose monitoring was continued for an additional 2 hours. Note that anandamide caused acute glucose intolerance and insulin resistance in wt and htgCB 1 Ϫ/Ϫ , but not in CB 1 Ϫ/Ϫ , mice. N ϭ 6 -8 animals/group. *P Ͻ .05 or # P Ͻ .005 from corresponding value in vehicle-pretreated mice. (B) GTT and IST were conducted as previously described in wildtype (wt), Ϫ/Ϫ hepatocytes is associated with increased CB 1 -stimulated GTP␥S binding.
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determined with an assay selective for human insulin, were similarly ϳ3 times higher in the htgCB 1 Ϫ/Ϫ mice ( Figure 3C ), whereas plasma levels of C-peptide were similar in the 2 strains, the latter indicating similar insulin secretion rates ( Figure 3D ). The hepatic levels of IDE were about half of that in CB 1 Ϫ/Ϫ littermates, and there was a parallel reduction in IDE catalytic activity in htgCB 1 Ϫ/Ϫ mice ( Figure 3E ), whereas levels of p-CEACAM1, another regulator of insulin degradation, 20 were similar in the 2 strains ( Figure 3E ). This suggests that reduced insulin degradation by IDE contributes to the moderate hyperinsulinemia of htgCB 1 Ϫ/Ϫ mice. Regulation of IDE by hepatic CB 1 was further indicated by the HFD-induced down-regulation of IDE expression in wild-type and htgCB 1 Ϫ/Ϫ , but not in CB 1 Ϫ/Ϫ , mice ( Figure 4A ) and by the ability of anandamide to downregulate IDE expression in vivo in wild-type mice ( Figure  4B ) or in vitro in HepG2 cells ( Figure 4C ). CB 1 -induced down-regulation of IDE expression was associated with increased serine-307 phosphorylation of IRS1 ( Figure 4A-C) , and it involved pertussis toxin-sensitive activation of G i␣ ( Figure 4C ).
CB 1 -Mediated Hepatic Insulin Resistance Manifests in Increased Glycogenolysis
The activity of the gluconeogenic enzymes glucose-6-phosphatase and PEPCK were similar in liver extracts from htgCB 1 Ϫ/Ϫ and CB 1 Ϫ/Ϫ mice, whereas glycogen phosphorylase a activity was increased by ϳ70% in the former (Supplementary Figure 3) , which suggests that glycogenolysis is a primary source of the increased hepatic glucose production. Indeed, hepatic glycogen at the end of the clamp was significantly lower in htgCB 1 Ϫ/Ϫ than in CB 1 Ϫ/Ϫ mice (Supplementary Table 1 ), most likely due to a compensatory increase in GLUT4 expression and a corresponding increase in glucose uptake in skeletal muscle and kidney, as revealed by [ 14 C]2-deoxyglucose uptake (Supplementary Figure 4) . Thus, overexpression of hepatic CB 1 leads to increased hepatic glucose production due to increased glycogenolysis, which is partially offset by a compensatory increase in glucose uptake, primarily into skeletal muscle.
CB 1 -Induced Hepatic Insulin Resistance is ER Stress Dependent
To test whether CB 1 -mediated insulin resistance may be via increased ER stress, we analyzed the hepatic level of the molecular chaperone Bip and the phosphorylation status of its downstream targets PERK 21 and the ␣ subunit of translation initiation factor-2 (eIF2␣), key indicators of ER stress. 22 The phosphorylation status of c-Jun and serine-307 of IRS1 was also monitored as indicators of the activation of c-Jun NH 2 -terminal kinase 1 (JNK1), which has been also linked to inhibition of insulin signaling. 23, 24 In agreement with earlier findings, 25 HFD in wild-type mice markedly increased Bip protein levels and the phosphorylation of PERK, eIF2␣, c-Jun, and IRS1 (serine-307) in the liver. There was a similar HFDinduced increase in Bip, p-PERK, p-eIF2␣, p-c-Jun, and p-serine-307IRS1 in the liver of htgCB 1 Ϫ/Ϫ , but not CB 1 Ϫ/Ϫ , mice ( Figure 4A ), whereas markers of 2 alternative pathways of ER stress, ATF6 and the spliced form of XBP1, were unaffected by genotype or HFD (not shown). To test whether activation of hepatic CB 1 induces ER stress, we treated wild-type mice with anandamide (10 mg/kg intraperitoneally) and killed them at various times posttreatment. Anandamide caused a rapid increase in Bip, p-c-Jun, and p-IRS1 that peaked at 30 -60 minutes and a slower, more prolonged increase in p-PERK and p-eIF2␣ ( Figure 4B) .
The chemical chaperone 4-phenyl butyric acid (PBA) reverses HFD-induced ER stress and insulin resistance. 26 In agreement with those findings, daily oral treatment of HFD-fed mice with 1 g/kg PBA for 20 days reversed the glucose intolerance ( Figure 5A ) and insulin resistance ( Figure 5B ) and also reversed the HFD-induced decrease in IDE expression ( Figure 5C ), thus providing additional evidence for the role of IDE in insulin resistance and its regulation by ER stress. 
CB 1 Inhibits Insulin-Induced akt-2 Phosphorylation in Mouse and Human Hepatocytes in an ER Stress-Dependent Manner
Protein kinase B/akt-2 plays an obligatory role in insulin-induced hypoglycemia by down-regulating gluconeogenic gene expression 6 and increasing the activity of glycogen synthase. 15 Exposure of human or mouse isolated hepatocytes to 10 nmol/L insulin increased phosphorylation of akt-2 at the thre308 and ser473 sites, which was concentration-dependently inhibited by anandamide or the synthetic cannabinoid WIN55,212-2 in human hepatocytes and in hepatocytes from wild-type or htgCB 1 Ϫ/Ϫ , but not CB 1 Ϫ/Ϫ , mice ( Figure 6A ). The role of CB 1 was further verified by blocking the effect of anandamide with the CB 1 antagonist SR141716 ( Figure 6B ). The inhibition of akt-2 phosphorylation by anandamide is ER stress dependent. In mouse hepatocytes, shRNA knock- 
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down of eIF2␣ by 61.6% Ϯ 7.1% resulted in marked suppression of serine-307 phosphorylation of IRS1 (Figure 6C) , whereas insulin-induced akt-2 phosphorylation was enhanced and was resistant to inhibition by anandamide or WIN 55,212-2 ( Figure 6D ).
Anandamide Inhibits Insulin Signaling via Activation of Phlpp1
Anandamide inhibition of insulin-induced akt-2 phosphorylation in wild-type mouse hepatocytes was blocked by a phosphatase inhibitor cocktail ( Figure 7A ), suggesting that anandamide promotes dephosphorylation of akt-2 by a phosphatase. The PH domain leucinerich repeat protein phosphatase-1 (Phlpp1) has been implicated in the dephosphorylation of akt-2. 27, 28 In mouse hepatocytes with an siRNA-induced, 68.8% Ϯ 1.3% knockdown of Phlpp1, insulin-induced akt-2 phosphorylation was enhanced and the inhibitory effect of anandamide was blunted ( Figure 7B ). Hepatic levels of Phlpp1 protein were increased by HFD in a CB 1 -dependent manner (Figure 4A ) and were also increased following in vivo treatment with anandamide ( Figure 4B ). In wild-type mouse hepatocytes, anandamide increases Phlpp1 expression via the ER stress response, as indicated by its blunted effect in cells with shRNA-mediated knockdown of eIF2␣ ( Figure  7C ). CB 1 is a G i /G o -coupled receptor, and the action of anandamide involves activation of G i␣ ( Figure 7D ).
Up-regulation of Hepatic CB 1 in Human Nonalcoholic Fatty Liver Disease
The effects of cannabinoids observed in human hepatocytes predicated the presence of CB 1 in human liver. Indeed, CB 1 mRNA could be detected by real-time PCR in liver biopsy tissue from 5 patients with no liver pathology, and a 34.2-fold Ϯ 9.7-fold increase (P Ͻ .05) in CB 1 mRNA relative to these controls was observed in tissue from 26 patients with nonalcoholic fatty liver disease. Increased expression of CB 1 protein in fatty versus nonfatty livers could also be documented by immunohistochemistry (Supplementary Figure 5) .
Discussion
Increased activity of the endocannabinoid/CB 1 system has emerged as a pathogenic factor in visceral obesity. 29, 30 A common complication of obesity is insulin resistance, and CB 1 blockade not only reduces weight and adiposity, but also improves insulin sensitivity both in obese subjects 8 and animals, [31] [32] [33] suggesting a role for endocannabinoids in glycemic control. Mice with selective deletion of CB 1 in hepatocytes become obese on HFD but remain glucose tolerant and insulin sensitive, whereas mice that express CB 1 only in hepatocytes remain lean on HFD but are insulin resistant, suggesting a weight-independent effect of hepatic CB 1 on insulin sensitivity. 13 Here we provide in vivo and in vitro evidence that endocannabinoids acting via hepatic CB 1 contribute to diet-induced hepatic insulin resistance by inhibiting both insulin signaling and clearance. Hepatic CB 1 activate the serine/threonine phosphatase Phlpp1 via the Bip/PERK/ eIF2␣ ER stress pathway, which suppresses insulin signaling by counteracting insulin-induced akt-2 phosphorylation. Hepatic CB 1 also induce serine-307 phosphorylation of IRS1, which inhibits insulin signaling. 34 Furthermore, activation of hepatic CB 1 suppresses insulin clearance via reducing the expression of the IDE.
HFD-induced hepatic insulin resistance, as revealed by a euglycemic hyperinsulinemic clamp, is dependent on the presence of CB 1 in hepatocytes (Figure 2) , activation of which suppresses insulin signaling, resulting in increased glucose production. Hepatic CB 1 are not only necessary but also sufficient to mediate hepatic insulin resistance; CB 1 Ϫ/Ϫ mice with selective hepatic reexpression of CB 1 are hyperglycemic and hyperinsulinemic relative to their CB 1 Ϫ/Ϫ littermates. These mice are insulin resistant even on normal diet, probably due to the transgenic overexpression of hepatic CB 1 to levels similar to those in normal mice on HFD 13, 35 ( Figure 1C) , and their insulin resistance is further increased by HFD (Figure 2) , likely mediated by the parallel increase in hepatic anandamide (Supplementary Figure 1) . The other endocannabinoid, 2-arachidonoyl glycerol, was elevated in the liver of a different experimental model on HFD; however, the magnitude of glucose intolerance was somewhat mitigated in those ApoE Ϫ/Ϫ mutants compared with wild-type mice on the same HFD. 36 The finding of a robust up-regulation of hepatic CB 1 expression in people with nonalcoholic fatty liver disease (Supplementary Figure 5) , along with evidence for CB 1 -mediated inhibition of insulin signaling in human hepatocytes ( Figure 6A ), suggests a similar regulatory function of CB 1 in the human liver. Indeed, marijuana smoking was shown more than 30 years ago to induce insulin resistance, 37 and cannabis also induces insulin resistance in rodents. 38 The key role of hepatic CB 1 in insulin resistance is further indicated by the finding that transgenic reexpression of hepatic CB 1 in CB 1 Ϫ/Ϫ mice rescues the ability of acute in vivo treatment with anandamide to induce insulin resistance ( Figure 1A ).
The increased hepatic glucose production of htgCB 1 Ϫ/Ϫ mice could be attributed to increased glycogenolysis rather than gluconeogenesis, based on ex vivo measurement of glycogen phosphorylase versus glucose-6-phosphatase and PEPCK activities, respectively (Supplementary Figure 3) . Nevertheless, a possible contribution of gluconeogenesis cannot be excluded, because regulation may also occur at the level of fructose 2,6-biphosphatase. Indeed, in a recent study in rat and human isolated hepatocytes, direct activation of CB 1 receptors by 2-arachidonoylglycerol was found to increase glucose-6-phosphatase and PEPCK gene expression as well as glucose production. 39 However, the relative contribution of gluconeogenesis and glycogenolysis to regulated glucose production may be different under in vitro and in vivo conditions. Also, enzyme activities were not measured and the possible contribution of glycogenolysis to the observed increase in glucose production was not explored in the previously described study. Future studies of glucose fluxes could provide a more definitive answer in this regard.
Although diet-induced glucose intolerance is predominantly attributable to hepatic insulin resistance, CB 1 can also inhibit glucose uptake into skeletal muscle 40, 41 and adipose tissue 42, 43 and inhibit insulin signaling in pancreatic beta cells. 44 The relative contributions of these targets to glycemic control by endocannabinoids may be different in rodents and humans and remain to be further explored.
The importance of reduced insulin clearance and IDE as pathogenic factors in diabetes is suggested by reports of an association of type 2 diabetes with loss of function mutations in IDE 45 or with polymorphisms in the IDE gene. 46, 47 Plasma levels of both endogenous and exogenous insulin were higher and hepatic IDE protein and activity levels were lower in htgCB 1 Ϫ/Ϫ than in CB 1 Ϫ/Ϫ mice ( Figure 3E ). The HFD-induced decrease in IDE depends on the presence of CB 1 in hepatocytes ( Figure 4A ), and the role of CB 1 in regulating IDE expression is further indicated by anandamide down-regulation of IDE in the liver in vivo and in HepG2 cells. Furthermore, obesityrelated insulin resistance and reduced IDE expression are both reversed by the chemical chaperone PBA, 26 which links ER stress to IDE expression. These findings represent the first direct link among a specific diabetogenic signal, hepatic CB 1 activation, and reduced insulin clearance via down-regulation of IDE. It is well established that obesity is accompanied by activation of the ER stress response in the liver, 25, 48, 49 which inhibits insulin signaling. 25 Activation of CB 1 can also induce ER stress, as documented recently in human glioma cells. 50 Because obesity leads to activation of the endocannabinoid/CB 1 system, 12, 29, 35 we hypothesized that the ER stress response in obesity may be mediated by endocannabinoids acting via hepatic CB 1 . This hypothesis is now supported by both in vivo and in vitro evidence.
Under in vivo conditions, HFD induces the expression of the chaperone Bip and increases the phosphorylation of its downstream targets PERK and eIF2␣, a key pathway of ER stress involved in suppressing protein translation, 51 whereas ATF6 and XBP1, key components of 2 additional arms of the ER stress response involved in protein folding and degradation, 51 appear unaffected. The effects of HFD on the Bip/PERK/eIF2␣ pathway are CB 1 dependent, because they are detectable in the liver of wild-type and htgCB 1 Ϫ/Ϫ , but not CB 1 Ϫ/Ϫ , mice ( Figure  4A ). CB 1 involvement is further supported by the in vivo action of anandamide to induce Bip expression and PERK and eIF2␣ phosphorylation ( Figure 4B ).
In primary cultured mouse hepatocytes, shRNA knockdown of eIF2␣ abrogated the ability of CB 1 agonists to inhibit insulin-induced akt-2 phosphorylation ( Figure  6D ) or to induce the expression of Phlpp1 ( Figure 7C ), a serine/threonine phosphatase involved in the dephosphorylation of akt-2. 27, 28 Furthermore, HFD-induced serine-307 phosphorylation of IRS1, which negatively regulates akt, 25 depends on the presence of CB 1 in hepatocytes ( Figure 4A ), and anandamide directly increases IRS1 serine phosphorylation ( Figure 4B and C) . These findings outline the signaling pathway engaged by hepatic CB 1 to inhibit the antiglycemic action of insulin: activation of hepatic CB 1 triggers ER stress, which inhibits insulin signaling by suppressing p-akt-2 via serine phosphorylation of IRS1 and at the same time promoting the dephosphorylation of p-akt-2 via activation of Phlpp1.
The possible role of JNK1 in hepatic ER stress and insulin resistance is complex. The protective role of germline deletion of JNK1 against obesity and insulin resistance 23, 24 could be attributed to loss of JNK1 activity in the brain, 52 whereas selective hepatic deletion of JNK1 has the opposite effect, that is, an increase in insulin resistance. 53 Thus, activation of JNK by CB 1 ( Figure 4A and B) is unlikely to contribute to the parallel development of hepatic insulin resistance. This is further suggested by our observation that pretreatment of mice with the JNK inhibitor BI-78D3 54 failed to prevent anandamide-induced glucose intolerance (not shown).
The ability of a peripherally restricted CB 1 R antagonist to reverse obesity-related insulin resistance has highlighted the importance of an overactive peripheral endocannabinoid system in the metabolic consequences of 
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obesity 33 and is also compatible with the role of hepatic CB 1 in this effect, as shown here. The present findings identify hepatic CB 1 as a potential novel molecular target for the pharmacotherapy of insulin resistance.
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